Bicara Therapeutics Inc.
BCAX
$9.32
-$0.11-1.17%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 03/31/2024 | ||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -- | -- | -- | -- | |
| Cost of Revenue | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | |
| SG&A Expenses | 123.07% | 116.13% | 83.87% | 87.75% | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | 171.81% | 94.62% | 116.45% | 84.43% | |
| Operating Income | -171.81% | -94.62% | -116.45% | -84.43% | |
| Income Before Tax | -194.03% | -67.04% | 23.48% | -49.78% | |
| Income Tax Expenses | 7,100.00% | 3,620.00% | -- | -- | |
| Earnings from Continuing Operations | -194.58% | -68.46% | 23.48% | -49.80% | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | -194.58% | -68.46% | 23.48% | -49.80% | |
| EBIT | -171.81% | -94.62% | -116.45% | -84.43% | |
| EBITDA | -171.92% | -94.70% | -116.34% | -84.31% | |
| EPS Basic | 96.43% | 98.05% | 95.81% | -23.91% | |
| Normalized Basic EPS | 96.43% | 98.07% | 95.81% | -23.90% | |
| EPS Diluted | 96.43% | 98.05% | 95.81% | -23.91% | |
| Normalized Diluted EPS | 96.43% | 98.07% | 95.81% | -23.90% | |
| Average Basic Shares Outstanding | 8,147.24% | 8,538.83% | 1,724.15% | 20.89% | |
| Average Diluted Shares Outstanding | 8,147.24% | 8,538.83% | 1,724.15% | 20.89% | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |